Drug Trial Radar · NCT05448001
Clinical Trial to Evaluate the Efficacy and Safety of JP-1366 in Patients With Gastric Ulcer
Last checked: Nov 19, 2026Latest source record: Aug 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
329
Actual
Start
Sep 19, 2022
Primary completion
Jul 10, 2024
Study completion Jul 19, 2024
Sponsor
- Lead sponsor
- Onconic Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 7, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Multi-center, Randomized, Double-Blind, Active-Controlled, Parallel Group, Phase III Clinical Trial to Evaluate the Efficacy and Safety of JP-1366 in Patients with Gastric Ulcer
Conditions
- Gastric Ulcer
Interventions
JP-1366 20mgDrug
JP-1366 20 mg 1 capsule, Lansoprazole 30 mg placebo 1 capsule before meal
Lansoprazole 30mgDrug
JP-1366 20 mg placebo 1 capsule, Lansoprazole 30 mg 1 capsule before meal
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cumulative complete healing rate for ulcer confirmed by upper gastrointestinal endoscopy by Week 8Time frame: Week 8
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Korea University Kuro Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.